DexCom, Inc. (DXCM) Free Cash Flow CAGR:148.66%(TTM)
The free cash flow cagr for DexCom, Inc. (DXCM) is +148.66% over the latest trailing 12-month period. Free cash flow CAGR uses precomputed cash-flow statement history.
The free cash flow cagr for DexCom, Inc. (DXCM) stock is 148.66% over the past 12 months. The 3 year average growth rate is 50.88% and the 5 year cagr is 43.37%. Free cash flow CAGR measures how DexCom, Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
DXCM Free Cash Flow CAGR Chart
DexCom, Inc. (DXCM)
DXCM Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $630.70M | $1.08B | +$446.50M | +70.79% | +70.79% |
| 2024 | $511.90M | $630.70M | +$118.80M | +23.21% | +23.21% |
| 2023 | $304.70M | $511.90M | +$207.20M | +68.00% | +68.00% |
| 2022 | $53.30M | $304.70M | +$251.40M | +471.67% | +471.67% |
| 2021 | $276.60M | $53.30M | $-223.30M | -80.73% | -80.73% |
| 2020 | $134.50M | $276.60M | +$142.10M | +105.65% | +105.65% |
| 2019 | $56.10M | $134.50M | +$78.40M | +139.75% | +139.75% |
| 2018 | $26.00M | $56.10M | +$30.10M | +115.77% | +115.77% |
| 2017 | $500.00K | $26.00M | +$25.50M | +5100.00% | +5100.00% |
| 2016 | $15.70M | $500.00K | $-15.20M | -96.82% | -96.82% |
| 2015 | $7.40M | $15.70M | +$8.30M | +112.16% | +112.16% |
| 2014 | $-5.50M | $7.40M | +$12.90M | +0.00% | N/A |
| 2013 | $-42.60M | $-5.50M | +$37.10M | +0.00% | N/A |
| 2012 | $-38.13M | $-42.60M | $-4.47M | +0.00% | N/A |
| 2011 | $-49.54M | $-38.13M | +$11.40M | +0.00% | N/A |
| 2010 | $-42.38M | $-49.54M | $-7.16M | +0.00% | N/A |
| 2009 | $-39.94M | $-42.38M | $-2.44M | +0.00% | N/A |
| 2008 | $-36.65M | $-39.94M | $-3.29M | +0.00% | N/A |
| 2007 | $-47.09M | $-36.65M | +$10.44M | +0.00% | N/A |
| 2006 | $-27.23M | $-47.09M | $-19.86M | +0.00% | N/A |
| 2005 | $-14.19M | $-27.23M | $-13.04M | +0.00% | N/A |
| 2004 | $-9.87M | $-14.19M | $-4.32M | +0.00% | N/A |
Quarterly Free Cash Flow — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $449.00M | +133.7% | +363.8% |
| Q4 2025 | $192.10M | -66.8% | +8.7% |
| Q3 2025 | $579.40M | +177.4% | +556.2% |
| Q2 2025 | $208.90M | +115.8% | -2.1% |
| Q1 2025 | $96.80M | -45.2% | -36.4% |
| Q4 2024 | $176.80M | +100.2% | +118.0% |
| Q3 2024 | $88.30M | -58.6% | -59.6% |
| Q2 2024 | $213.30M | +40.1% | +62.5% |
| Q1 2024 | $152.30M | +87.8% | +88.7% |
| Q4 2023 | $81.10M | -62.9% | +17.5% |
| Q3 2023 | $218.80M | +66.6% | +18.3% |
| Q2 2023 | $131.30M | +62.7% | +61.5% |
| Q1 2023 | $80.70M | +17.0% | +363.7% |
| Q4 2022 | $69.00M | -62.7% | +169.5% |
| Q3 2022 | $185.00M | +127.6% | +32.9% |
| Q2 2022 | $81.30M | +365.7% | +305.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach